Business Description
PureTech Health PLC
NAICS : 325412
SIC : 2834
ISIN : GB00BY2Z0H74
Total Employee Number:
56Description
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 14.16 | |||||
Equity-to-Asset | 0.58 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | -0.32 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 1.11 | |||||
Beneish M-Score | -2.65 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 32.6 | |||||
3-Year EBITDA Growth Rate | 5.8 | |||||
3-Year EPS without NRI Growth Rate | -3.1 | |||||
3-Year FCF Growth Rate | 20.3 | |||||
3-Year Book Growth Rate | -15.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 27.72 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 95.81 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 50.37 | |||||
9-Day RSI | 51.68 | |||||
14-Day RSI | 51.5 | |||||
3-1 Month Momentum % | 21.08 | |||||
6-1 Month Momentum % | 10.14 | |||||
12-1 Month Momentum % | 8.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.59 | |||||
Quick Ratio | 6.59 | |||||
Cash Ratio | 5.99 | |||||
Days Sales Outstanding | 152.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 4.6 | |||||
Shareholder Yield % | 1.48 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -2112.05 | |||||
Net Margin % | -2354.97 | |||||
EBITDA Margin % | -1321.61 | |||||
FCF Margin % | -1823.6 | |||||
OCF Margin % | -1823.6 | |||||
ROE % | -29.18 | |||||
ROA % | -19.05 | |||||
ROIC % | -37.39 | |||||
3-Year ROIIC % | 7.22 | |||||
ROC (Joel Greenblatt) % | -476.52 | |||||
ROCE % | -12.2 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shiller PE Ratio | 32.41 | |||||
PS Ratio | 87.47 | |||||
PB Ratio | 1.36 | |||||
Price-to-Tangible-Book | 1.37 | |||||
EV-to-EBIT | -2.47 | |||||
EV-to-EBITDA | -2.6 | |||||
EV-to-Forward-EBITDA | -1.11 | |||||
EV-to-Revenue | 34.42 | |||||
EV-to-Forward-Revenue | 127.74 | |||||
EV-to-FCF | -1.89 | |||||
Price-to-GF-Value | 0.25 | |||||
Price-to-Median-PS-Value | 0.86 | |||||
| Price-to-Net-Current-Asset-Value | 5.25 | |||||
| Price-to-Net-Cash | 7.72 | |||||
Earnings Yield (Greenblatt) % | -40.49 | |||||
FCF Yield % | -19.77 |
PureTech Health PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PureTech Health PLC Stock Events
| Event | Date | Price (£) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-08-28 09:00 | In 61 days | ||
| Second quarter earnings results for 2026 | 2026-08-28 | In 60 days | ||
| General meeting for 2026 | 2026-06-10 11:00 | 1.24 (-1.12%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-04-29 09:00 | 1.30 (+3.99%) | ||
| Annual report for 2025 | 2026-04-29 | 1.30 (+3.99%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-29 | 1.30 (+3.99%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-11 11:20 | 1.25 (+0.64%) | ||
| 44th Annual J.P. Morgan Healthcare Conference | 2026-01-14 19:30 | 1.33 (+1.22%) | ||
| Second quarter earnings conference call for 2025 | 2025-08-28 09:00 | 1.34 (+0.98%) | ||
| Second quarter earnings results for 2025 | 2025-08-28 | 1.34 (+0.98%) |
Show
Entries
Press Release
Articles on PureTech Health PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers